Sidley represented the underwriters in the US$190.2 million initial public offering by Pharvaris N.V. (NASDAQ: PHVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Morgan Stanley, BofA Securities, and SVB Leerink acted as joint book-running managers of the offering and Oppenheimer & Co. and Kempen & Co acted as co-managers.
The Sidley team was led by Global Life Sciences partner Frank Rahmani (Palo Alto and San Francisco) and Capital Markets partner Sam Gandhi (New York), and associates Alex Csordas, Nicole Garrett, and Brandon Harmer (each New York). Other critical support was provided by Life Sciences Transactions partner Tom Duley (San Francisco) and associate Elliott Blufer (Los Angeles); Executive Compensation and Benefits partner Corey Perry (Chicago) and associate Richard Schneider (Chicago); FDA Regulatory partner Torrey Cope (Washington, D.C.) and counsel Susan Stolzer (New York); and Tax partner Rachel Kleinberg (Palo Alto) and associate Kimberly Goldman (Los Angeles).
